Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CD3 bispecific antibody true-killer combo

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 25, 2023 1:16pm

175 Views

Post# 35245621

RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

Johnson & Johnson's JNJ-8902 — a CD3 x TMEFF2 bispecific - appears to have been retired.

TMEFF2 is a transmembrane protein with EGF which was speculated to be a tumor immuosuppressor - which ONCY's pelareorep has demonstrated as capable of achieving in ONCY's AWARE-1 study and now potentially enhancing as a bispecific with a CD3 targeted antibody.

https://endpts.com/jj-quietly-punts-a-pair-of-early-stage-bispecifics-for-solid-tumors/

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec